The Elegant Challenger - What short-acting psychedelics in TRD trials measure compared with longer-session programs

Short-acting psychedelic trial design for treatment-resistant depression aims to make outcomes measurable by tightly controlling session structure, expectancy, and blinding. The comparison centers on two different architectures: inhaled 5-MeO-DMT (GH001) versus psilocybin 25 mg with longer, therapist-supported sessions (COMP006), plus parallels to other short-session 5-MeO-DMT approaches like BPL-003. Short-acting protocols use briefer psychoactive peaks, avoid formal psychotherapy during the acute window, and rely on remote or centralized blinded MADRS raters (and in some cases an active comparator). The goal is to reduce confounds that can inflate placebo and expectancy signals, a problem highlighted by earlier MDMA trials where many participants could correctly guess assignment. The tradeoff is external validity. Design choices that lower noise in trials may also narrow the kind of patient populations the results apply to, especially regarding prior psychedelic experience and how unblinding risk behaves in real-world clinics. The piece links these points to published work on blinding integrity and to broader meta-analytic findings about effect sizes under better blinding controls.